RNAZ

Transcode Therapeutics, Inc. (RNAZ) - Q2 2024 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2024. Transcode Therapeutics is a clinical-stage biopharmaceutical company focused on oncology, utilizing a proprietary iron-oxide nanoparticle delivery platform (TTX) to target RNA in tumors. The Company's lead candidate, TTX-MC138, targets miRNA-10b to inhibit metastatic cell survival. The Company has no approved products and has not generated any revenue from product sales.

Key Financial Metrics

Note: The Company reported no revenue. Grant income recognized was $0 for Q2 2024 and $27,057 for the six months ended June 30, 2024, compared to $868,345 in the prior year period.

Material Changes vs. Prior Period

• Operating Expenses: Total operating expenses decreased by approximately $1.6 million for the six months ended June 30, 2024, compared to the same period in 2023. This reduction was driven by lower materials, supplies, consulting, and purchased services costs, partially offset by increased share-based compensation and clinical trial expenses.
• Grant Income: Grant income decreased significantly as the NIH SBIR Award program concluded in March 2024. No grant income was recognized in Q2 2024.
• Capital Structure: The Company completed a 1-for-40 reverse stock split in January 2024. Shares outstanding increased from 627,448 at year-end 2023 to 7,265,658 at June 30, 2024, due to equity issuances and warrant exercises.
• Liquidity: Cash balances increased slightly from $2.77 million at December 31, 2023, to $3.35 million at June 30, 2024, primarily due to net proceeds of approximately $6.87 million from equity financings during the six-month period.

Guidance, Outlook, and Risks

• Clinical Progress: The Company received FDA authorization to proceed with a Phase I/II clinical trial for TTX-MC138 in April 2024. Enrollment is expected to begin in Q3 2024. Phase 0 trial data showed accumulation of the drug in metastatic lesions and a 66% reduction in miRNA-10b levels in a patient's blood.
• Liquidity and Going Concern: Management has concluded there is substantial doubt about the Company's ability to continue as a going concern for 12 months from the filing date. Current cash plus proceeds from a July 2024 offering (approx. $2.4 million) is expected to fund operations only into late 2024. Additional capital is required to continue operations.
• Nasdaq Delisting Risk: On August 13, 2024, the Company received notice from Nasdaq regarding non-compliance with the Minimum Bid Price Requirement ($1.00 per share). Due to two reverse stock splits in the prior two years, the Company is not eligible for a standard compliance period and faces potential delisting. An appeal to a Hearings Panel is pending.
• Collaborations: The Company entered into a collaboration with Debiopharm in January 2024 and is in negotiations with MD Anderson regarding a strategic collaboration agreement.
• Internal Controls: The Company disclosed that its disclosure controls and procedures were not effective as of June 30, 2024, due to material weaknesses in internal control over financial reporting that remain unremediated.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $3.35 million cash balance plus the $2.4 million July 2024 proceeds to fund the Phase I trial and operations through late 2024.
• Delisting Status: Monitor the outcome of the appeal to the Nasdaq Hearings Panel regarding the Minimum Bid Price Requirement.
• Capital Needs: Assess the terms and likelihood of success for future equity or debt financings required to bridge the funding gap beyond late 2024.
• Internal Controls: Review the progress of remediation efforts for the material weaknesses in internal controls over financial reporting.
• Clinical Milestones: Track the commencement of the Phase I/II trial and patient enrollment rates for TTX-MC138.